Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedInvestigator attribution was split into a standalone name entry and new metadata lines (Last verified, Last known status). The page also introduces new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a standardized label for Intervention/Treatment.SummaryDifference2%

- Check19 days agoChange DetectedA new revision tag labeled Revision: v3.5.5 appears, replacing the prior Revision: v3.5.4.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page now displays Revision: v3.5.4, updating the revision label from the previous v3.5.3. This reflects a new entry in the page's revision history.SummaryDifference0.1%

- Check55 days agoChange DetectedThe interface revision tag was updated from v3.5.2 to v3.5.3. This reflects a minor platform update with no changes to the study details presented on the page.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision: v3.5.2 now appears on the page, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check98 days agoChange DetectedRevision history updated: added Revision v3.5.0 and removed Revision v3.4.2.SummaryDifference0.1%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.